261 related articles for article (PubMed ID: 20651610)
1. Expression and mutational status of c-kit in thymic epithelial tumors.
Petrini I; Zucali PA; Lee HS; Pineda MA; Meltzer PS; Walter-Rodriguez B; Roncalli M; Santoro A; Wang Y; Giaccone G
J Thorac Oncol; 2010 Sep; 5(9):1447-53. PubMed ID: 20651610
[TBL] [Abstract][Full Text] [Related]
2. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
3. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
[TBL] [Abstract][Full Text] [Related]
4. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas.
Giaccone G; Rajan A; Ruijter R; Smit E; van Groeningen C; Hogendoorn PC
J Thorac Oncol; 2009 Oct; 4(10):1270-3. PubMed ID: 20197733
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 receptor expression in thymic malignancies.
Girard N; Teruya-Feldstein J; Payabyab EC; Riely GJ; Rusch VW; Kris MG; Zakowski MF
J Thorac Oncol; 2010 Sep; 5(9):1439-46. PubMed ID: 20736806
[TBL] [Abstract][Full Text] [Related]
7. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Schirosi L; Nannini N; Nicoli D; Cavazza A; Valli R; Buti S; Garagnani L; Sartori G; Calabrese F; Marchetti A; Buttitta F; Felicioni L; Migaldi M; Rea F; Di Chiara F; Mengoli MC; Rossi G
Ann Oncol; 2012 Sep; 23(9):2409-2414. PubMed ID: 22357254
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and clinical significance of KIT(CD117) expression in thymic epithelial tumors in China.
Song N; Chen G; Zhang P; Liu M; He WX; Jiang GN
Asian Pac J Cancer Prev; 2012; 13(6):2745-8. PubMed ID: 22938452
[TBL] [Abstract][Full Text] [Related]
9. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
Suzuki E; Sasaki H; Kawano O; Endo K; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
Jpn J Clin Oncol; 2006 Jun; 36(6):351-6. PubMed ID: 16762968
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
[TBL] [Abstract][Full Text] [Related]
11. [Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective].
Ströbel P; Knop S; Einsele H; Müller-Hermelink HK; Marx A
Verh Dtsch Ges Pathol; 2007; 91():177-86. PubMed ID: 18314613
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Girard N; Shen R; Guo T; Zakowski MF; Heguy A; Riely GJ; Huang J; Lau C; Lash AE; Ladanyi M; Viale A; Antonescu CR; Travis WD; Rusch VW; Kris MG; Pao W
Clin Cancer Res; 2009 Nov; 15(22):6790-9. PubMed ID: 19861435
[TBL] [Abstract][Full Text] [Related]
13. C-KIT mutation in thymic carcinomas.
Terzi N; Yilmaz I; Batur S; Yegen G; Yol C; Arikan E; Oz A
Pol J Pathol; 2020; 71(2):120-126. PubMed ID: 32729302
[TBL] [Abstract][Full Text] [Related]
14. Thymic tumors: relevant molecular data in the clinic.
Girard N
J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S291-5. PubMed ID: 20859122
[TBL] [Abstract][Full Text] [Related]
15. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma.
Hirabayashi H; Fujii Y; Sakaguchi M; Tanaka H; Yoon HE; Komoto Y; Inoue M; Miyoshi S; Matsuda H
Int J Cancer; 1997 Nov; 73(5):639-44. PubMed ID: 9398039
[TBL] [Abstract][Full Text] [Related]
16. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ
Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical KIT (CD117) expression in thymic epithelial tumors.
Nakagawa K; Matsuno Y; Kunitoh H; Maeshima A; Asamura H; Tsuchiya R
Chest; 2005 Jul; 128(1):140-4. PubMed ID: 16002927
[TBL] [Abstract][Full Text] [Related]
18. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas.
Pan CC; Chen PC; Chiang H
J Pathol; 2004 Mar; 202(3):375-81. PubMed ID: 14991904
[TBL] [Abstract][Full Text] [Related]
19. Thymic carcinoma arising in thymoma is associated with alterations in immunohistochemical profile.
Kuo TT; Chan JK
Am J Surg Pathol; 1998 Dec; 22(12):1474-81. PubMed ID: 9850173
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O
Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
